The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy

J Immunol Res. 2015:2015:106904. doi: 10.1155/2015/106904. Epub 2015 Feb 26.

Abstract

Few studies have correlated serum biomarkers with renal histology, the gold standard for renal activity, in lupus nephritis (LN). We tested a panel of autoantibodies and complement at the time of kidney biopsy and after treatment. Anti-dsDNA, anti-nucleosome, anti-ribosome P, and anti-C1q antibodies and C3/C4 were measured in 107 patients with LN at the time of renal biopsy and after 6-12 months and were correlated with clinical/histological parameters. At multivariate analysis, high titers of anti-C1q antibodies or of anti-dsDNA antibodies (P = 0.005, OR = 8.67, CI: 2.03-37.3) were the independent predictors that discriminate proliferative from nonproliferative LN. All the immunological parameters, except anti-ribosome, showed a significant correlation with activity index but not with chronicity index. Only anti-C1q showed a significant correlation with the amount of proteinuria (R = 0.2, P = 0.03). None of the immunological parameters were predictive of remission at 6 and 12 months. We found that anti-C1q alone or in combination with anti-dsDNA emerged as the most reliable test in differentiating proliferative and nonproliferative LN. Anti-C1q was the only test correlated with the clinical presentation of LN. After treatment, the titre of the autoantibodies was significantly reduced, but none was predictive of remission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Autoantibodies / blood
  • Autoantibodies / immunology*
  • Biomarkers
  • Biopsy
  • Female
  • Humans
  • Kidney / immunology*
  • Kidney / pathology*
  • Lupus Nephritis / blood
  • Lupus Nephritis / diagnosis*
  • Lupus Nephritis / drug therapy
  • Lupus Nephritis / immunology*
  • Male
  • Middle Aged
  • Prognosis
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Substances

  • Autoantibodies
  • Biomarkers